CTS will implement the Bio-Rad Geenius HIV 1/2 supplemental assay on Monday September 21, 2020. The newly licensed Geenius test is an immunochromatographic assay designed to confirm and differentiate individual antibodies to Human Immunodeficiency Virus Types 1 and 2. The assay will be replacing the HIV-1 Western blot and HIV-2 EIA assays which are performed on samples with a reactive result on a licensed HIV 1/2 screening test.
Read all about it on the Communication page by clicking this link: Communications
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
As a service to our partners, CTS provides a copy of all licenses and accreditations on our website....
Reminder - Dr. Buff Mair is the new CTS Medical Director. Several of the CTS client forms specify li...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...